Najmeh Parhizgari, Farhad Rezaei, Mohammad-Reza Khatami, Sayed Mahdi Marashi, Mohammad Farahmand, Farzane Behnezhad, Monireh Derakhshani, Fatemeh Ajami-Nezhad and Talat Mokhtari-Azad*
Background: In spite of antiviral prophylaxis regimens, Cytomegalovirus (CMV) remains a major reason for morbidity and allograft failure in kidney transplant recipients. This study aimed to investigate the incidence of early or late onset of CMV viremia in kidney transplant recipients and evaluate the correlation of laboratory findings and graft origin with CMV viremia.
Methods: In this prospective case-control study, 192 kidney recipients were evaluated for the timing and potential risk factors based on detectable CMV viremia (≥200 copies/ml) and all-correlates were assessed using multivariate logistic regression models.
Results: 153 participants from examined patients were eligible to enter the study. The risk of CMV viremia with viral loads ≥200 copies/ml was receiving a graft from a deceased donor. Importantly, CMV viremia mostly occurred 4 months after transplantation, while the patients were expected to be on CMV prophylaxis.
Conclusions: Receiving a renal graft from a deceased donor significantly raises the incidence of viremia in renal transplant patients. The median month of CMV viremia occurrence was month 4th after transplantation. Serum testing showed a significant increase in creatinine and a decrease in platelets in the CMV positive group compared to the control group. Our results indicated that the viremia has not affected the survival of the allograft or patient.HTML PDF
Share this article
Journal of Blood & Lymph received 443 citations as per Google Scholar report